Rapid growth of Merkel cell carcinoma after treatment with rituximab.

Abstract	Merkel cell carcinoma is an uncommon neuroendocrine carcinoma of the skin. We report a case of rapid growth of Merkel cell carcinoma after treatment with rituximab, a new anti-CD20 monoclonal antibody, for acquired factor VIII inhibitor. We propose that rituximab may place patients at higher risk for aggressive Merkel cell carcinoma thus necessitating the need for increased long-term surveillance of these patients.
Authors	Marla L Wirges, Frank Saporito, Jennifer Smith
Journal	Journal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 5 Issue 2 Pg. 180-1 (Feb 2006) ISSN: 1545-9616 [Print] United States
PMID	16485888 (Publication Type: Case Reports, Journal Article)
Chemical References	Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents Rituximab
Topics	Aged Antibodies, Monoclonal (adverse effects) Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents (adverse effects) Carcinoma, Merkel Cell (pathology) Female Humans Rituximab Skin Neoplasms (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!